BREAKING NEWS: Plus Therapeutics has been selected for funding by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs (CDMRP). The award is expected to commence in Q3 2024 and will support the planned expansion of the Company’s clinical trial for pediatric brain cancer. Full Press Release: https://bit.ly/PSTV_PR #braincancer #pediatriconcology #clinicaltrials
Recent Posts
- Recognizing Rare Disease Day
- Rethinking Radiation Therapy: A Targeted Approach for Hard‑to‑Treat Cancers
- Plus Therapeutics Announces Approval of New AMA Category III CPT® Code Supporting Use of Convection‑Enhanced Delivery with REYOBIQ™
- Navigating the Future of Radiopharmaceuticals
- Precision Medicine and the Next Wave of Innovation in CNS Cancers
Recent Comments